Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
Swiss Cancer Institute
National Heart, Lung, and Blood Institute (NHLBI)
University of Rochester
National Cancer Institute (NCI)
Amgen
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center